Ovid Therapeutics’ (OVID) Buy Rating Reiterated at BTIG Research

BTIG Research restated their buy rating on shares of Ovid Therapeutics (NASDAQ:OVID) in a research note published on Thursday,Benzinga reports. BTIG Research currently has a $4.00 price objective on the stock.

A number of other analysts have also recently commented on OVID. Wall Street Zen raised Ovid Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Roth Mkm assumed coverage on shares of Ovid Therapeutics in a research note on Thursday, December 11th. They set a “buy” rating and a $3.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Ovid Therapeutics in a report on Thursday, January 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $2.00 target price on shares of Ovid Therapeutics in a research note on Monday, December 22nd. Finally, Lifesci Capital began coverage on shares of Ovid Therapeutics in a report on Monday, December 22nd. They issued an “outperform” rating and a $4.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $4.38.

Ovid Therapeutics Price Performance

NASDAQ:OVID opened at $2.30 on Thursday. The company has a debt-to-equity ratio of 0.09, a current ratio of 8.97 and a quick ratio of 8.97. Ovid Therapeutics has a one year low of $0.24 and a one year high of $2.72. The company has a fifty day moving average price of $1.79 and a 200 day moving average price of $1.61. The stock has a market cap of $163.78 million, a P/E ratio of -7.42 and a beta of 0.25.

Ovid Therapeutics (NASDAQ:OVID) last released its quarterly earnings data on Wednesday, March 18th. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.16. Ovid Therapeutics had a negative return on equity of 23.98% and a negative net margin of 240.11%.The business had revenue of $0.72 million during the quarter, compared to the consensus estimate of $0.06 million. Analysts anticipate that Ovid Therapeutics will post -0.4 earnings per share for the current year.

Institutional Investors Weigh In On Ovid Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. LPL Financial LLC boosted its stake in Ovid Therapeutics by 150.0% in the 4th quarter. LPL Financial LLC now owns 30,000 shares of the company’s stock worth $49,000 after purchasing an additional 18,000 shares during the period. Bank of America Corp DE raised its stake in shares of Ovid Therapeutics by 49.7% in the 4th quarter. Bank of America Corp DE now owns 56,733 shares of the company’s stock valued at $53,000 after purchasing an additional 18,841 shares during the period. Benin Management CORP acquired a new stake in shares of Ovid Therapeutics in the 4th quarter valued at about $31,000. Geode Capital Management LLC lifted its holdings in shares of Ovid Therapeutics by 3.7% in the fourth quarter. Geode Capital Management LLC now owns 672,004 shares of the company’s stock valued at $1,096,000 after purchasing an additional 23,984 shares in the last quarter. Finally, Private Advisor Group LLC bought a new stake in shares of Ovid Therapeutics in the third quarter valued at about $33,000. 72.24% of the stock is owned by institutional investors.

More Ovid Therapeutics News

Here are the key news stories impacting Ovid Therapeutics this week:

• Positive Sentiment: Analysts raised the firmwide price target to $4.87 (a 14.29% increase) — a materially higher target that signals stronger upside vs. the current price and may support buying interest. Ovid Therapeutics (OVID) price target increased by 14.29% to 4.87
• Positive Sentiment: BTIG reaffirmed its “Buy” rating and set a $4.00 price target, implying roughly 70%+ upside from current levels — another institutional vote of confidence that can attract momentum buyers. BTIG reaffirmed buy, $4 PT
• Positive Sentiment: Lifesci Capital raised several quarterly EPS forecasts (Q2–Q4 2026 were nudged higher) and reiterated an “Outperform” rating with a $4.00 target — upgrades to near-term estimates and a maintained outperform stance reinforce bullish analyst sentiment. Lifesci Capital research notes on OVID
• Positive Sentiment: Brokerage consensus remains favorable — a recent summary shows a consensus “Buy” rating from covering firms, which tends to support investor confidence. Ovid given consensus ‘Buy’ by brokerages
• Negative Sentiment: Offsetting the upbeat notes, Lifesci trimmed its Q1 2026 EPS forecast (to -$0.11 from -$0.08), which is a nearer‑term earnings disappointment risk and could pressure sentiment if short-term execution concerns persist. Lifesci cut Q1 2026 EPS estimate

About Ovid Therapeutics

Ovid Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need.

The company’s lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome.